Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine
NCT00513968
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
27
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Hepatitis B
Interventions
GENETIC:
a mixed plasmid DNA (HB-110)
DRUG:
Adefovir
Sponsor
Genexine, Inc.